ORYZON raises its share capital

Oryzon Genomics, S.A. (MAD: ORY) ("Oryzon" or the "Company"), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today announced a capital increase of 7,273,000 new common shares (the “New Shares”) at a price of 2.75 euros per share, for an aggregate amount of EUR 20 Million (the “Capital Increase”). The Capital Increase was carried out through a private placement. The Company intends to use the net proceeds from the Capital Increase to finance the Company’s research and development of clinical pipeline candidates, continue with the preparations for a potential dual listing on Nasdaq in the future and other general corporate purposes.

Subject to completion of certain customary closing procedures, the admission of the new shares to trading on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges, through the Spanish Automated Quotation System (Sistema de Interconexión Bursátil) is expected on June 26, 2020, and the trading of the New Shares is expected to commence on June 29, 2020.

The Company has submitted to the Spanish National Securities Market Commission (CNMV) a regulatory announcement regarding the approval of the Capital Increase by the Board of Directors and the main terms and results of the Capital Increase, which is available on the CNMV’s website at www.cnmv.es.

Jefferies International Limited was Sole Global Coordinator and Joint Bookrunner, Kempen & Co was Joint Bookrunner, and Andbank España, S.A.U. was Co-Manager in the Capital Increase. Gómez-Acebo & Pombo Abogados, S.L.P. (the Company’s Spanish counsel) and Davis Polk & Wardwell LLP (the Company’s U.S. and English counsel) have acted as legal advisors to the Company, and White & Case LLP has acted as Spanish, English and U.S. legal advisor to the Placement Agents.

Important Information

The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

With respect to Member States of the European Economic Area, no action has been taken or will be taken to permit a public offering of the securities referred to in this press release. Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of Article 1(4) of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”) or, otherwise, in cases not requiring the publication of a prospectus under Article 3 of the Prospectus Regulation.

This press release and the information it contains are being made only to and are directed for (i) persons in Member States of the European Economic Area who are qualified investors within the meaning of article 2(e) of the Prospectus Regulation (“Qualified Investors”), (ii) persons outside the United Kingdom, (iii) persons outside the United States, and (iv) in the United Kingdom, Qualified Investors who are (a) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (b) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies”, “unincorporated associations”, etc.) or (c) other persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (i), (ii), (iii) and (iv) together being referred to as “Relevant Persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release relates will only be engaged in with, and is only available to, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this press release or any of its contents.

The New Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold in the United States of America absent registration or an applicable exemption from registration under the Securities Act and applicable state securities law. The securities have not been registered, and there is no intention to register any securities referred to herein in the United States or to make any public offering of securities of the Company in the United States.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com

ESTE ANUNCIO TIENE MERO CARÁCTER INFORMATIVO. NO CONSTITUYE UN DOCUMENTO DE REGISTRO NI UN FOLLETO Y NO DEBE SER TRATADO COMO UNA OFERTA DE NINGÚN TIPO. ESTA COMUNICACIÓN NO ES PARA SU DIFUSIÓN, PUBLICACIÓN NI DISTRIBUCIÓN, DIRECTA O INDIRECTA, EN LOS ESTADOS UNIDOS DE AMÉRICA, CANADÁ, AUSTRALIA, JAPÓN, SUDÁFRICA O CUALQUIER OTRA JURISDICCIÓN EN LA QUE DICHA DISTRIBUCIÓN, PUBLICACIÓN O DIFUSIÓN SEA ILÍCITA.

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY. THIS DOCUMENT IS NEITHER A REGISTRATION DOCUMENT NOR A PROSPECTUS AND SHOULD NOT BE CONSTRUED AS AN OFFER OF ANY KIND. THIS COMMUNICATION IS NOT FOR RELEASE, PUBLICATION NOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SAID DISTRIBUTION, PUBLICATION OR RELEASE IS UNLAWFUL.